‘Improved Non-Invasive Routes Of Administration Of Peptides’  

Hosted by Joël Richard, Senior Vice President, Peptides, Head of CMC Development Dreux Site, Ipsen

Thursday 16^th February 2017 | 2pm GMT – UK Time. Can’t Make the Date? Still Register and receive the recording afterwards !

Our webinar speaker:

Joël Richard, Senior Vice President, Peptides, Head of CMC Development Dreux Site, Ipsen: Advances In Non-Invasive Routes Of Administration Of Peptides: Focus On Successful Oral Technologies Progressing In The Clinic And Future Challenges

• Peptide delivery landscape and importance of non-invasive routes of administration
• Overview of transdermal and buccal delivery of peptides
• Focus on oral peptide delivery: main challenges and technological approaches, permeation enhancers, nanoparticles
• Lessons learnt from clinical studies: addressing the challenges of peptide stability in the GI tract and oral bioavailability
• Future challenges of oral delivery: bioavailability, dosing frequency, food effects, cost of goods and impact of API demand

Benefits to Attending:

• Boost your knowledge about novel non-invasive peptide administration routes
• Learn more about successful oral peptide technologies
• Hear about the outcomes of peptide clinical studies

Please click here to register for the webinar

Terms & Conditions:

This webinar is exclusively for Peptides professionals. If you are unsure whether you should attend please contact [email protected] for clarification. In very rare circumstances the event may be cancelled, postponed or the time changed. We will endeavour to contact you by tele and email, it is therefore imperative that you provide the correct information. Failure to provide all the details we require on the registration form may result in your registration being cancelled.
By registering for this event you agree to be added to Oxford Global’s mailing list. If you would prefer not to receive emails about Oxford Global’s events and free webinars you can unsubscribe at any time.

Data Protection Act (1998)
Please note the personal information provided by you will be held on a database by Oxford Global in accordance with the Data Protection Act 1998. Data may be shared with the selected partners for the event that you are attending however we will not disclose personal data that you have provided to any other third party and the information you supply to us will only be used by Oxford Global and selected partners to contact you regarding training/events or our other services.

Dr Joël Richard , Senior Vice President, Peptides in IPSEN (France). He is globally leading all the CMC development activities of both injectable and oral peptide-based products, including APIs and drug products, with major franchises in Oncology, Endocrinology and Neurology. Dr Richard has more than 25 years of experience in chemistry and biopharmaceutical R&D, including several global senior positions in various Biotech and Pharma companies, such as: Vice President, Drug Product Development in Ipsen (France) (2008-2011), Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany) (2005-2008), Vice President Research, and Europe R&D Director at Ethypharm (France) (2001-2004), COO at Mainelab (France), a drug delivery company he co-founded, which was specialized in developing solvent-free processes for protein delivery systems (1999-2001) Since 1996, Dr Richard has focused his research activity on new formulation technologies and drug delivery systems (such as microspheres, nanoparticles, nanocapsules, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable protein and peptide formulations. Dr Richard has published 64 peer-reviewed scientific papers, 7 book chapters and 2 review editorials in various fields (colloids and interfaces, drug delivery, supercritical fluids, protein formulations, nanoparticles, sustained-release formulations . . .). He is the author of more than 100 international communications and 53 patent families.